Shenoy Lab

Shalini Shenoy, MD, MBBS

My academic focus is on the development of safer less toxic methods of hematopoietic stem cell transplantation in children. Toward this, I am investigating reduced intensity transplantation for children with hemoglobinopathy (sickle cell disease and thalassemia) using the best available related or alternate donors.  

Based on a preliminary multi-center trial that was previously completed, a national trial of unrelated donor marrow transplantation for severe sickle cell disease is ongoing under the Bone Marrow Transplant Clinical Trials Network (BMT CTN) and is called the SCURT Trial (BMT CTN 0601). 

Another trial for thalassemia has just been completed under the Thalassemia Clinical research Network (TCRN) and Pediatric Blood and Marrow transplant Consortium (PBMTC) – called the URTH trial. We are now exploring reduced intensity transplantation for non-malignant disorders including hemoglobinopathy using minimally mismatched marrow or cord blood donors in a separate study (01-0923).

Principal investigator

Shalini  Shenoy, MD, MBBS

Shalini Shenoy, MD, MBBS

Professor of Pediatrics, Hematology & Oncology
Director, Stem Cell Transplant & Cellular Therapy Program

Recent publications

  • Hyperthyroidism following transplantation and SARS-CoV-2 exposureElnaggar, M. & Shenoy, S., Dec 2023, In: Pediatric Blood and Cancer. 70, 12, e30713.Research output: Contribution to journal › Letter › peer-review
  • Mixed donor chimerism following stem cell transplantation for sickle cell diseaseShah, N. C., Rangarajan, H. G., Ngwube, A. & Shenoy, S., Nov 1 2023, In: Current opinion in hematology. 30, 6, p. 187-193 7 p.Research output: Contribution to journal › Review article › peer-review
  • Children's Oncology Group's 2023 blueprint for research: Cellular therapy and stem cell transplantationKitko, C. L., Bollard, C. M., Cairo, M. S., Chewning, J., Fry, T. J., Pulsipher, M. A., Shenoy, S., Wall, D. A. & Levine, J. E., Sep 2023, In: Pediatric Blood and Cancer. 70, S6, e30577.Research output: Contribution to journal › Article › peer-review
  • Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse eventsTakahashi, T., Al-Kofahi, M., Jaber, M., Bratrude, B., Betz, K., Suessmuth, Y., Yu, A., Neuberg, D. S., Choi, S. W., Davis, J., Duncan, C., Giller, R., Grimley, M., Harris, A. C., Jacobsohn, D., Lalefar, N., Farhadfar, N., Pulsipher, M. A., Shenoy, S., Petrovic, A., & 8 othersSchultz, K. R., Yanik, G. A., Blazar, B. R., Horan, J. T., Watkins, B., Langston, A., Qayed, M. & Kean, L. S., Aug 24 2023, In: Blood. 142, 8, p. 700-710 11 p.Research output: Contribution to journal › Article › peer-review
  • Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCTGeerlinks, A. V., Scull, B., Krupski, C., Fleischmann, R., Pulsipher, M. A., Eapen, M., Connelly, J. A., Bollard, C. M., Pai, S. Y., Duncan, C. N., Kean, L. S., Baker, K. S., Burroughs, L. M., Andolina, J. R., Shenoy, S., Roehrs, P., Hanna, R., Talano, J. A., Schultz, K. R., Stenger, E. O., & 7 othersLin, H., Zoref-Lorenz, A., McClain, K. L., Jordan, M. B., Man, T. K., Allen, C. E. & Marsh, R. A., Jul 25 2023, In: Blood Advances. 7, 14, p. 3725-3734 10 p.Research output: […]